$SLS News Article - Targeting The National Cancer Institute's #1- Ranked Cancer Antigen: SELLAS' Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1
https://marketwirenews.com/news-releases/targ...71985.html